Bristol Myers Squibb (BMY) has been a topic of interest for investors recently for several reasons. The company plans to cut costs by $2 billion by 2027, despite issuing weak guidance. Several financial entities, including Y Intercept Hong Kong Ltd and Exchange Capital Management Inc, have either taken or increased positions in the company. This suggests a mixed outlook among investors. Despite a 7.2% stock drop, BMY is considered among the best drug stocks and a good long-term, low-risk investment. Although BMY faces a potential dip in 2025 revenue due to incoming generics, the firm has outperformed Q4 earning estimates, and the FDA has approved two of its drugs, Opdivo Qvantig™ and COBENFY™. Strong Q4 financial performance alongside weak future outlook reflect high volatility in the stock. However, long term, BMY remains an attractive option for investors due to its robust dividend payments.
Bristol-Myers Squibb BMY News Analytics from Mon, 06 May 2024 07:00:00 GMT to Sat, 01 Mar 2025 09:32:37 GMT -
Rating 0
- Innovation 6
- Information 7
- Rumor -3
